Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.

Gauthier, S; Alam, J; Fillit, H; Iwatsubo, T; Liu-Seifert, H; Sabbagh, M; Salloway, S; Sampaio, C; Sims, J R; Sperling, B; Sperling, R; Welsh-Bohmer, K A; Touchon, J; Vellas, B; Aisen, P

Gauthier, S; Alam, J; Fillit, H; Iwatsubo, T; Liu-Seifert, H; Sabbagh, M; Salloway, S; Sampaio, C; Sims, J R; Sperling, B; Sperling, R; Welsh-Bohmer, K A; Touchon, J; Vellas, B; Aisen, P.

Affiliation

Gauthier S; Serge Gauthier, McGill Center for Studies in Aging, Verdun QC, Canada, serge.gauthier@mcgill.ca.

J Prev Alzheimers Dis ; 6(3): 164-168, 2019.

Article in En | MEDLINE | ID: mdl-31062826

Subject(s)

Alzheimer Disease/drug therapy; Drug Development; Advisory Committees; Animals; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Treatment Outcome

Key words

Alzheimer's disease; amyloid; tau; therapeutics; trial design

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Drug Development Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Prev Alzheimers Dis Year: 2019 Document type: Article

Fulltext

XML

PubMed Links

Search on Google